Changes in the clinical epidemiology of HIV infection in the United States: Implications for the clinician

  • Kate Buchacz
  • Maria Rangel
  • Rachel Blacher
  • John T. Brooks
Article

Abstract

The HIV epidemic in the United States continues to affect racial/ethnic minorities disproportionately and is increasing among men who have sex with men. Late HIV diagnosis remains common. To reduce HIV transmission and facilitate early linkage to care and antiretroviral treatment, the Centers for Disease Control and Prevention recommends universal voluntary HIV screening for all persons ages 13 to 64 years in public and private care settings. Recent studies demonstrate dramatic reductions in morbidity and mortality with widespread use of highly active combination antiretroviral therapy (cART), and some document improved outcomes when cART is initiated with CD4 cell count > 350 cells/mm3. As patients live longer, they are increasingly affected by chronic diseases, notably cardiovascular and renal disease, diabetes, and non-AIDS-defining cancers. Providers should ensure patients undertake preventive lifestyle changes (eg, smoking cessation, exercise, weight loss, dietary modification) and undergo recommended screening tests to reduce their risk for these important comorbidities.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: HIV prevalence estimates—United States, 2006. MMWR Morb Mortal Wkly Rep 2008, 57:1073–1076.Google Scholar
  2. 2.
    Hall HI, Song R, Rhodes P, et al.: Estimation of HIV incidence in the United States. JAMA 2008, 300:520–529.PubMedCrossRefGoogle Scholar
  3. 3.
    Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2006. Vol 18. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008.Google Scholar
  4. 4.
    Centers for Disease Control and Prevention: Trends in HIV/AIDS diagnoses among men who have sex with men—33 states, 2001–2006. MMWR Morb Mortal Wkly Rep 2008, 57:681–686.Google Scholar
  5. 5.
    Ogbuanu IU, Torres ME, Kettinger L, et al.: Epidemiological characterization of individuals with newly reported HIV infection: South Carolina, 2004–2005. Am J Public Health 2007, 98:1–7. doi:10.2105/AJPH.2006.104323.Google Scholar
  6. 6.
    Keruly JC, Moore RD: Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007, 45:1369–1374.PubMedCrossRefGoogle Scholar
  7. 7.
    Marks G, Crepaz N, Janssen RS: Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006, 20:1447–1450.PubMedCrossRefGoogle Scholar
  8. 8.
    Branson BM, Handsfield HH, Lampe MA, et al.: Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006, 55:1–17.PubMedGoogle Scholar
  9. 9.
    Palella FJ Jr, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Patel K, Hernan MA, Williams PL, et al.: Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008, 46:507–515.PubMedCrossRefGoogle Scholar
  11. 11.
    Lima VD, Hogg RS, Harrigan PR, et al.: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007, 21:685–692.PubMedCrossRefGoogle Scholar
  12. 12.
    Ewings FM, Bhaskaran K, McLean K, et al.: Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008, 22:89–95.PubMedCrossRefGoogle Scholar
  13. 13.
    May M, Sterne JA, Sabin C, et al.: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21:1185–1197.PubMedGoogle Scholar
  14. 14.
    Bhaskaran K, Hamouda O, Sannes M, et al.: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300:51–59.PubMedCrossRefGoogle Scholar
  15. 15.
    US Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: USGoogle Scholar
  16. 16.
    Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society—USA panel. JAMA 2008, 300:555–570.PubMedCrossRefGoogle Scholar
  17. 17.
    Gras L, Kesselring AM, Griffin JT, et al.: CD4 cell counts of 800 cells/mm 3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm 3 or greater. J Acquir Immune Defic Syndr 2007, 45:183–192.PubMedCrossRefGoogle Scholar
  18. 18.
    Jaen A, Esteve A, Miro JM, et al.: Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS cohort (Spain). J Acquir Immune Defic Syndr 2008, 47:212–220.PubMedGoogle Scholar
  19. 19.
    Baker JV, Peng G, Rapkin J, et al.: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008, 22:841–848.PubMedCrossRefGoogle Scholar
  20. 20.
    Emery S, Neuhaus JA, Phillips AN, et al.: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197:1133–1144.PubMedCrossRefGoogle Scholar
  21. 21.
    ElSadr WM, Lundgren JD, Neaton JD, et al.: CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283–2296.PubMedCrossRefGoogle Scholar
  22. 22.
    Lichtenstein KA, Armon C, Buchacz K, et al.: Initiation of antiretroviral therapy at CD4 cell counts >/= 350 cells/mm 3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008, 47:27–35.PubMedGoogle Scholar
  23. 23.
    Phillips AN, Leen C, Wilson A, et al.: Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007, 370:1923–1928.PubMedCrossRefGoogle Scholar
  24. 24.
    DART Trial Team: Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS 2008, 22:237–247.Google Scholar
  25. 25.
    Ananworanich J, Gayet-Ageron A, Le Braz M, et al.: CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006, 368:459–465.PubMedCrossRefGoogle Scholar
  26. 26.
    Lau B, Gange SJ, Moore RD: Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm 3. J Acquir Immune Defic Syndr 2007, 44:179–187.PubMedCrossRefGoogle Scholar
  27. 27.
    Hooshyar D, Hanson DL, Wolfe M, et al.: Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS 2007, 21:2093–2100.PubMedGoogle Scholar
  28. 28.
    Kourtis AP, Bansil P, Posner SF, et al.: Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994–2003 Nationwide Inpatient Sample. Pediatrics 2007, 120:e236–e243.PubMedCrossRefGoogle Scholar
  29. 29.
    Buchacz K, Baker R, Moorman A, et al.: Trends in rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS 2008, 22:1345–1356.PubMedGoogle Scholar
  30. 30.
    Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008, 22:489–496.PubMedGoogle Scholar
  31. 31.
    Sobieszczyk ME, Hoover DR, Anastos K, et al.: Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2008, 48:272–280.PubMedGoogle Scholar
  32. 32.
    Justice AC: Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med 2006, 14:159–163.PubMedGoogle Scholar
  33. 33.
    Tien PC, Schneider MF, Cole SR, et al.: Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study. AIDS 2007, 21:1739–1745.PubMedCrossRefGoogle Scholar
  34. 34.
    Anastos K, Lu D, Shi Q, et al.: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007, 45:34–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Friis-Moller N, Reiss P, Sabin CA, et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723–1735.PubMedCrossRefGoogle Scholar
  36. 36.
    Sabin CA, Worm SW, Weber R, et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1426.PubMedCrossRefGoogle Scholar
  37. 37.
    Kaplan RC, Kingsley LA, Sharrett AR, et al.: Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007, 45:1074–1081.PubMedCrossRefGoogle Scholar
  38. 38.
    Carr A, Grund B, Neuhaus J, et al.; SMART Study Investigators: Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS 2008, 22:257–267.PubMedCrossRefGoogle Scholar
  39. 39.
    Wand H, Calmy A, Carey DL, et al.: Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445–2453.PubMedGoogle Scholar
  40. 40.
    Patel P, Hanson DL, Sullivan PS, et al.: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008, 148:728–736.PubMedGoogle Scholar
  41. 41.
    Silverberg MJ, Neuhaus J, Bower M, et al.: Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007, 21:1957–1963.PubMedCrossRefGoogle Scholar
  42. 42.
    Kirk GD, Merlo C, O’Driscoll P, et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103–110.PubMedCrossRefGoogle Scholar
  43. 43.
    Mocroft A, Kirk O, Gatell J, et al.: Chronic renal failure among HIV-1-infected patients. AIDS 2007, 21:1119–1127.PubMedGoogle Scholar
  44. 44.
    Wyatt CM, Winston JA, Malvestutto CD, et al.: Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007, 21:2101–2103.PubMedCrossRefGoogle Scholar
  45. 45.
    Lucas GM, Lau B, Atta MG, et al.: Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008, 197:1548–1557.PubMedCrossRefGoogle Scholar
  46. 46.
    Kalayjian RC, Franceschini N, Gupta SK, et al.: Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008, 22:481–487.PubMedGoogle Scholar
  47. 47.
    Young B, Buchacz K, Baker RK, et al.: Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007, 6:178–187.CrossRefGoogle Scholar
  48. 48.
    Goicoechea M, Liu S, Best B, et al.: Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008, 197:102–108.PubMedGoogle Scholar
  49. 49.
    Weinbaum CM, Lyerla R, Mackellar DA, et al.: The Young Men’s Survey phase II: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2008, 98:839–845.PubMedCrossRefGoogle Scholar
  50. 50.
    Spradling PR, Richardson JT, Buchacz K, et al.: Chronic hepatitis C virus (HCV) infection in the HIV Outpatient Study, 1996–2005: more testing, less prevalence [abstract 905]. Presented at the 45th Annual Meeting of the Infectious Diseases Society of America (IDSA). San Diego, CA; October 4–7, 2007.Google Scholar
  51. 51.
    Danta M, Brown D, Bhagani S, et al.: Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007, 21:983–991.PubMedCrossRefGoogle Scholar
  52. 52.
    Lima VD, Geller J, Bangsberg DR, et al.: The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007, 21:1175–1183.PubMedGoogle Scholar
  53. 53.
    Horberg MA, Silverberg MJ, Hurley LB, et al.: Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008, 47:384–390.PubMedGoogle Scholar
  54. 54.
    Lazo M, Gange SJ, Wilson TE, et al.: Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007, 45:1377–1385.PubMedCrossRefGoogle Scholar
  55. 55.
    Zetola NM, Klausner JD: Syphilis and HIV infection: an update. Clin Infect Dis 2007, 44:1222–1228.PubMedCrossRefGoogle Scholar
  56. 56.
    Scott KC, Philip S, Ahrens K, et al.: High prevalence of gonococcal and chlamydial infection in men who have sex with men with newly diagnosed HIV infection: an opportunity for same-day presumptive treatment. J Acquir Immune Defic Syndr 2008, 48:109–112.PubMedCrossRefGoogle Scholar
  57. 57.
    Zuckerman RA, Lucchetti A, Whittington WL, et al.: Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007, 196:1500–1508.PubMedCrossRefGoogle Scholar
  58. 58.
    Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790–799.PubMedCrossRefGoogle Scholar
  59. 59.
    Centers for Disease Control and Prevention: Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003, 52:1–24.Google Scholar
  60. 60.
    Schachter J, Moncada J, Liska S, et al.: Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008, 35:637–642.PubMedGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • Kate Buchacz
    • 1
  • Maria Rangel
  • Rachel Blacher
  • John T. Brooks
  1. 1.Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations